Oryzon Genomics S.A. (BME:ORY)
2.690
-0.100 (-3.58%)
Apr 7, 2026, 5:35 PM CET
Oryzon Genomics Revenue
In the year 2025, Oryzon Genomics had annual revenue of 10.93M EUR with 48.59% growth. Oryzon Genomics had revenue of 10.93M in the quarter ending December 31, 2025, with 48.59% growth.
Revenue
10.93M
Revenue Growth
+48.59%
P/S Ratio
19.07
Revenue / Employee
237.71K
Employees
46
Market Cap
208.51M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.93M | 3.58M | 48.59% |
| Dec 31, 2024 | 7.36M | -6.83M | -48.15% |
| Dec 31, 2023 | 14.19M | -1.51M | -9.60% |
| Dec 31, 2022 | 15.70M | 5.08M | 47.88% |
| Dec 31, 2021 | 10.62M | 1.09M | 11.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.52B |
| Almirall | 1.11B |
| Laboratorios Farmaceuticos Rovi | 743.48M |
| Laboratorio Reig Jofre | 336.68M |
| Clínica Baviera | 304.91M |
| Prim, S.A. | 253.56M |
| Pharma Mar | 221.39M |
| Atrys Health | 145.00M |
Oryzon Genomics News
- 5 weeks ago - ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025 - GlobeNewsWire
- 3 months ago - ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors - GlobeNewsWire
- 4 months ago - ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting - GlobeNewsWire
- 5 months ago - ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025 - GlobeNewsWire
- 5 months ago - ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease - GlobeNewsWire
- 5 months ago - ORYZON to Participate in Upcoming Events in November - GlobeNewsWire
- 6 months ago - ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder - GlobeNewsWire
- 6 months ago - ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors - GlobeNewsWire